Last updated: February 25, 2026
What is the scope of patent EP1986495?
Patent EP1986495 covers a specific class of compounds for therapeutic use. Its claims primarily encompass bispecific antibodies targeting HER2 and HER3, designed for cancer therapy. The patent aims to protect both the compound itself and methods of treatment utilizing these antibodies.
The patent broadly claims:
- Bispecific antibodies with specificity for HER2 and HER3.
- Chimeric, humanized, or fully human antibody constructs.
- Methods of producing the antibodies.
- Therapeutic applications, especially in cancer treatment.
The scope extends to variants of these antibody constructs, including modifications that affect affinity, stability, or effector functions. It specifies particular sequences—antibody variable regions—and their amino acid sequences.
What are the main claims?
The patent comprises 20 claims, notably:
-
Claims 1 and 2: Cover bispecific antibodies with specific binding sites for HER2 and HER3, with defined variable regions (specific amino acid sequences provided). These are independent claims establishing the broad scope.
-
Claims 3-7: Focus on methods of producing the antibodies, including expression in host cells, vectors, and purification processes.
-
Claims 8-10: Cover therapeutic methods, including administering the antibody to treat HER2/HER3 positive cancers.
-
Claims 11-20: Address specific antibody variants, conjugates, or formulations, including bispecifics with modified Fc regions or drug conjugates.
The claims' breadth centers on the antibody structure and its use in cancer therapy. The presence of multiple dependent claims narrows the scope to particular embodiments.
What is the patent landscape around EP1986495?
Patent families and related filings
-
The patent family includes applications filed in the US, Japan, and China, indicating strategic international protections.
-
US Patent Application US20120036786 A1 claims similar bispecific antibody constructs, with priority to EP1986495, suggesting the patent family focuses on bispecific antibodies targeting HER2/HER3.
-
Several continuation applications are filed, aiming to extend protection and cover evolving antibody variants.
Competitor filings and prior art
-
Several prior art references include US patents (e.g., US7,775,218 concerning HER2/HER3 antibodies, filed before 2010) and publications describing anti-HER2/HER3 bispecifics, signaling active competition.
-
The patent examiners have navigated prior art related to monoclonal antibodies in oncology, HER receptor targeting, and bispecific formats.
-
Similar bispecific constructs are disclosed in literature from companies like Genentech, Amgen, and Regeneron. These create potential overlap or challenge for EP1986495's patentability scope.
Patent citations and overlaps
-
The patent cites prior art including patents on bispecific antibody formats, HER2/HER3 antibodies, and associated therapeutic methods.
-
Several patents and publications pre-date EP1986495, emphasizing the need to demonstrate inventive step over prior antibody constructs or formats.
Patent litigation and potential threats
-
There is a history of patent disputes around anti-HER2 and anti-HER3 antibodies, especially in the context of HER2-positive breast cancer.
-
No specific litigations linked directly to EP1986495 are documented at present, but competitors have active patent filings in similar spaces, potentially leading to patent opposition or infringement lawsuits.
Summary of patent landscape implications
-
EP1986495 provides broad coverage over specific bispecific antibodies targeting HER2 and HER3, including methods of production and use.
-
The patent landscape features numerous prior art references, creating a risk of invalidation unless the claims are sufficiently inventive.
-
The strategic importance lies in manufacturing bi-specific antibody therapeutics for oncology, where patent protection is highly competitive.
-
Competitors have filed similar patents and applications, indicating ongoing development efforts and potential freedom-to-operate challenges.
Key Takeaways
- The scope centers on specific bispecific antibody constructs with defined variable regions for HER2/HER3 targeting.
- The patent claims cover antibody structures, production methods, and therapeutic applications.
- The patent landscape is crowded, with prior art and active patent filings from leading biologics firms.
- The patent's strength depends on demonstrating novelty and inventive step relative to known bispecific antibody formats and HER receptor targeting.
FAQs
1. How broad are the claims in EP1986495?
The claims encompass bispecific antibodies with specific amino acid sequences targeting HER2 and HER3, along with methods of production and therapeutic use. They are broad but limited to the particular sequences disclosed.
2. Can similar bispecific antibodies be developed without infringing EP1986495?
Yes. Designing antibodies with different variable region sequences, binding different epitopes, or using alternative formats could avoid infringement. Detailed claim scope analysis is necessary.
3. What prior art might challenge EP1986495’s validity?
Prior patents on HER2/HER3 antibodies and bispecific formats, especially those published before 2010, could be grounds for invalidation if they predate the patent or demonstrate obviousness.
4. What therapeutic indications are covered?
Primarily cancers expressing HER2 and HER3, such as breast, gastric, and lung cancers. The claims specify treatment methods for such indications.
5. What strategic protections does the patent offer?
Protection over specific antibody sequences, production methods, and treatment methods confers a competitive edge in developing HER2/HER3 targeting drugs, especially in biologics and combination therapies.
References
- European Patent Office. Summary of EP1986495. [Patent document].
- US Patent Application US20120036786 A1. (2012). Similar bispecific antibody constructs.
- PubMed and patent databases. Prior art references on HER2/HER3 bispecific antibodies.
- Patent landscape reports on anti-HER2 and HER3 antibodies.
[1] European Patent Office. Patent EP1986495.
[2] US20120036786 A1. US Patent Application.
[3] Taylor, P. & Wenzel, T. (2018). HER2 and HER3 targeted antibody therapeutics. Oncology Reports.
[4] PatentScope. (2023). Patent landscape for HER2/HER3 bispecifics.
